Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck”

15 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 15 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06557889
What this trial is testing

Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas

Who this might be right for
Squamous Cell Carcinoma of Head and Neck
Institut Claudius Regaud 86
Testing effectiveness (Phase 2)Study completedNCT02207530
What this trial is testing

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
AstraZeneca 112
Large-scale testing (Phase 3)Study completedNCT02369874
What this trial is testing

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

Who this might be right for
Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
AstraZeneca 736
Not applicableStudy completedNCT06771674
What this trial is testing

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

Who this might be right for
Oropharyngeal Squamous Cell Carcinoma
Hookipa Biotech GmbH 662
Large-scale testing (Phase 3)Active Not RecruitingNCT06082167
What this trial is testing

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Exelixis 600
Large-scale testing (Phase 3)Looking for participantsNCT06601335
What this trial is testing

AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Akeso 510
Large-scale testing (Phase 3)Active Not RecruitingNCT06295731
What this trial is testing

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)
Inhibrx Biosciences, Inc 410
Testing effectiveness (Phase 2)UnknownNCT05075122
What this trial is testing

Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Martin-Luther-Universität Halle-Wittenberg 75
Large-scale testing (Phase 3)Active Not RecruitingNCT04534205
What this trial is testing

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

Who this might be right for
Unresectable Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck Cancer
BioNTech SE 358
Testing effectiveness (Phase 2)Active Not RecruitingNCT05980000
What this trial is testing

Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma

Who this might be right for
Recurrent Head and Neck CancerRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Carcinoma+3 more
Washington University School of Medicine 37
Testing effectiveness (Phase 2)Looking for participantsNCT06769698
What this trial is testing

See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)
Regeneron Pharmaceuticals 120
Large-scale testing (Phase 3)Looking for participantsNCT06788990
What this trial is testing

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Who this might be right for
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics 650
Large-scale testing (Phase 3)Ended earlyNCT06790966
What this trial is testing

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Recurrent Head and Neck CancerMetastatic Head and Neck CancerHPV Positive Oropharyngeal Squamous Cell Carcinoma+2 more
PDS Biotechnology Corp. 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT02955290
What this trial is testing

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Who this might be right for
Advanced Head and Neck Squamous Cell CarcinomaLung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell Carcinoma+13 more
Roswell Park Cancer Institute 51
Testing effectiveness (Phase 2)Looking for participantsNCT06016920
What this trial is testing

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

Who this might be right for
HPV Positive Oropharyngeal Squamous Cell CarcinomaHNSCC
Nykode Therapeutics ASA 110